- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Danish Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
4
High return on equity, past performance and sound balance sheet.
4 companies
ChemoMetec
Market Cap: DKK 12.4b
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
CHEMM
DKK 712.50
7D
-10.0%
1Y
88.5%
Genmab
Market Cap: DKK 115.0b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,867.50
7D
1.5%
1Y
17.5%
Gubra
Market Cap: DKK 6.1b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 372.80
7D
-10.1%
1Y
-12.3%
Zealand Pharma
Market Cap: DKK 29.9b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 424.50
7D
-9.9%
1Y
-47.8%